Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 4/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30900681 | 0.87 | SPR (0.47) | SPRHDAC2VNN1CYP2C19CYP3A4 | |
| SCHEMBL3410221 | 0.85 | HDAC2 (0.41) | SPRHDAC2VNN1CYP2C19CYP3A4 | |
| SCHEMBL933548 | 0.80 | USP2 (0.41) | CYP2C19CYP3A4MAPK1MEN1KMT2A | |
| SCHEMBL20702446 | 0.80 | USP2 (0.40) | VNN1CYP2C19CYP3A4MAPK1MEN1 | |
| SCHEMBL31417910 | 0.80 | SPR (0.41) | SPRHDAC2VNN1CYP2C19CYP3A4 | |
| SCHEMBL31622147 | 0.80 | HDAC2 (0.40) | SPRHDAC2VNN1CYP2C19CYP3A4 | |
| SCHEMBL18711887 | 0.80 | SMN1; SMN2 (0.50) | CYP2C19CYP3A4MAPK1MEN1KMT2A | |
| SCHEMBL20702425 | 0.78 | SPR (0.38) | SPRHDAC2VNN1 | |
| SCHEMBL20702405 | 0.78 | SPR (0.38) | SPRHDAC2VNN1 | |
| SCHEMBL20702394 | 0.78 | SPR (0.38) | SPRHDAC2VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3672952-B1 | BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | claimed |
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-09-29 | — | — | US | claimed |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2022-09-27 | — | — | US | claimed |
| US-20200207720-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-07-02 | — | — | US | claimed |
| EP-3672952-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-07-01 | — | — | EP | claimed |
| WO-2019038215-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-28 | — | — | WO | claimed |
| EP-3672952-B1 | BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | disclosed |
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-09-29 | — | — | US | disclosed |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2022-09-27 | — | — | US | disclosed |
| US-20200207720-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-07-02 | — | — | US | disclosed |
| EP-3672952-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019038215-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-28 | — | — | WO | disclosed |
| US-8703761-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-04-22 | — | — | US | disclosed |
| EP-2559455-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| EP-2548618-A2 | Organic compounds | Novartis AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| US-20100022513-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | SPR 4674/4885HDAC2 1175/4885VNN1 3668/4885 |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | SPR 4376/4885HDAC2 2127/4885VNN1 3437/4885 |
| US-20100022513-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | SPR 3099/4885HDAC2 612/4885VNN1 2663/4885 |
| US-20200207720-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | SPR 4674/4885HDAC2 1175/4885VNN1 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.